Published in J Exp Med on August 01, 1974
The Raji cell radioimmune assay for detecting immune complexes in human sera. J Clin Invest (1976) 8.06
Natural antibody and complement mediate neutralization of influenza virus in the absence of prior immunity. J Virol (2007) 2.09
Mechanism of injury of virus-infected cells by antiviral antibody and complement: participation of IgG, F(ab')2, and the alternative complement pathway. J Exp Med (1976) 1.57
The complement system: its importance in the host response to viral infection. Microbiol Rev (1982) 1.44
Neutralization of Epstein-Barr virus by nonimmune human serum. Role of cross-reacting antibody to herpes simplex virus and complement. J Clin Invest (1982) 1.20
Differential mechanisms of complement-mediated neutralization of the closely related paramyxoviruses simian virus 5 and mumps virus. Virology (2008) 1.06
Immune complexes in human diseases: a review. Am J Pathol (1980) 1.05
Complement requirement for virus neutralization by antibody and reduced serum complement levels associated with experimental equine herpesvirus 1 infection. Infect Immun (1981) 0.90
Scanning and transmission electron microscopic studies of complement-mediated lysis and antibody-dependent cell-mediated cytolysis of herpes simplex virus-infected human fibroblasts. Am J Pathol (1980) 0.79
Editorial: Complement activation and disease. Br Med J (1976) 0.75
Effect of staphylococcal protein A on complement-potentiated neutralization of herpes simplex virus and immune lysis of virus-infected cells. Infect Immun (1975) 0.75
Synergy between the classical and alternative pathways of complement is essential for conferring effective protection against the pandemic influenza A(H1N1) 2009 virus infection. PLoS Pathog (2017) 0.75
Complement Evasion Strategies of Viruses: An Overview. Front Microbiol (2017) 0.75
A method of trace iodination of proteins for immunologic studies. Int Arch Allergy Appl Immunol (1966) 43.66
ISOLATION OF BETA IF-GLOBULIN FROM HUMAN SERUM AND ITS CHARACTERIZATION AS THE FIFTH COMPONENT OF COMPLEMENT. J Exp Med (1965) 15.47
ISOLATION AND DESCRIPTION OF THE FOURTH COMPONENT OF HUMAN COMPLEMENT. J Exp Med (1963) 7.42
Pathogenesis of chronic disease associated with persistent lymphocytic choriomeningitis viral infection. I. Relationship of antibody production to disease in neonatally infected mice. J Exp Med (1969) 6.03
Enharncement of the hemolytic activity of the second component of human complement by oxidation. J Exp Med (1967) 5.36
Surface markers on human B and T lymphocytes. II. Presence of Epstein-Barr virus receptors on B lymphocytes. J Exp Med (1973) 5.03
The pathogenesis of Aleutian disease of mink. I. In vivo viral replication and the host antibody response to viral antigen. J Exp Med (1969) 3.98
The morphology of virus-antibody interaction. Adv Virus Res (1969) 3.36
Infectious virus-antibody complex in the blood of chronically infected mice. J Exp Med (1966) 2.68
Molecular weights of coliphages and colip- hage DNA. II. Measurement of diffusion coefficients using optical mixing spectroscopy, and measurement of sedimentation coefficients. J Mol Biol (1970) 2.50
A comparison of methods for the molecular quantitation of the fourth component of human complement. Immunochemistry (1968) 2.44
The second component of human complement (C2): quantitative molecular analysis of its reactions in immune hemolysis. Immunochemistry (1970) 2.18
MOLECULAR MECHANISM OF FORMATION OF AN ANTIGEN-ANTIBODY COMPLEX. Nature (1965) 1.90
Complement components required for virus neutralization by early immunoglobulin antibody. Proc Natl Acad Sci U S A (1969) 1.72
Elevated gamma-globulin and increased antibody production in mice infected with lactic dehydrogenase virus. J Exp Med (1966) 1.71
Immune complex disease in chronic viral infections. J Exp Med (1971) 1.69
Neutralization of sensitized virus by purified components of complement. Proc Natl Acad Sci U S A (1970) 1.63
The morphological and biological effects of various antisera on avian infectious bronchitis virus. J Gen Virol (1968) 1.54
Persistent lymphocytic choriomeningitis viral infection. 3. Virus-anti-viral antibody complexes and associated chronic disease following transplacental infection. J Immunol (1970) 1.19
Production of ultrastructural membrane lesions by the fifth component of complement. J Exp Med (1971) 1.18
Immunofluorescence study of the mechanism of resistance to superinfection in mice carrying the lymphocytic choriomeningitis virus. J Pathol Bacteriol (1966) 1.15
Infectious virus-antibody complexes: interaction with anti-immunoglobulins, complement, and rheumatoid factor. J Exp Med (1971) 1.13
Equine infectious anemia: detection of infections virus-antibody complexes in the serum. Immunol Commun (1972) 1.10
Studies on Bacillus subtilis bacteriophage phi 15. Virology (1973) 0.99
Immune virolysis: effect of antibody and complement on C-type RNA virus. Science (1970) 0.97
Herpesvirus neutralization: the role of complement. J Immunol (1971) 0.93
Rate-zonal centrifugation of herpes simplex virus-antibody complexes. Virology (1971) 0.91
The fate of sensitized equine arteritis virus following neutralization by complement of anti-IgG serum. Virology (1973) 0.87
Letter: Epstein-Barr virus and infectious mononucleosis. Lancet (1973) 0.79
Virus-specific CD8+ cytotoxic T-lymphocyte activity associated with control of viremia in primary human immunodeficiency virus type 1 infection. J Virol (1994) 15.93
Inflammation and Alzheimer's disease. Neurobiol Aging (2000) 12.56
Antiviral pressure exerted by HIV-1-specific cytotoxic T lymphocytes (CTLs) during primary infection demonstrated by rapid selection of CTL escape virus. Nat Med (1997) 12.08
Selection of genetic variants of lymphocytic choriomeningitis virus in spleens of persistently infected mice. Role in suppression of cytotoxic T lymphocyte response and viral persistence. J Exp Med (1984) 10.66
Cellular localization of human immunodeficiency virus infection within the brains of acquired immune deficiency syndrome patients. Proc Natl Acad Sci U S A (1986) 8.45
The virology and immunobiology of lymphocytic choriomeningitis virus infection. Adv Immunol (1980) 6.24
Pathogenesis of chronic disease associated with persistent lymphocytic choriomeningitis viral infection. I. Relationship of antibody production to disease in neonatally infected mice. J Exp Med (1969) 6.03
Identification of alpha-dystroglycan as a receptor for lymphocytic choriomeningitis virus and Lassa fever virus. Science (1998) 5.83
Differential regulation of antiviral T-cell immunity results in stable CD8+ but declining CD4+ T-cell memory. Nat Med (2001) 5.74
Biology of cloned cytotoxic T lymphocytes specific for lymphocytic choriomeningitis virus: clearance of virus in vivo. J Virol (1984) 5.57
Molecular mimicry and autoimmune disease. Cell (1987) 5.31
Cytomegalovirus infects human lymphocytes and monocytes: virus expression is restricted to immediate-early gene products. Proc Natl Acad Sci U S A (1984) 4.56
Genomic and biological variation among commonly used lymphocytic choriomeningitis virus strains. J Gen Virol (1983) 4.45
Cytoimmunotherapy for persistent virus infection reveals a unique clearance pattern from the central nervous system. Nature (1986) 4.01
Lymphocytic choriomeningitis: production of antibody by "tolerant" infected mice. Science (1967) 4.01
Virus-induced immunosuppression: immune system-mediated destruction of virus-infected dendritic cells results in generalized immune suppression. J Virol (1995) 3.90
The reaction mechanism of human C5 in immune hemolysis. J Exp Med (1970) 3.83
Identification and characterization of the Epstein-Barr virus receptor on human B lymphocytes and its relationship to the C3d complement receptor (CR2). J Virol (1985) 3.76
Detection of human cytomegalovirus in peripheral blood lymphocytes in a natural infection. Science (1985) 3.69
Amino acid homology between the encephalitogenic site of myelin basic protein and virus: mechanism for autoimmunity. Science (1985) 3.68
Immunosuppression and resultant viral persistence by specific viral targeting of dendritic cells. J Exp Med (2000) 3.50
Initiation of human cytomegalovirus infection requires initial interaction with cell surface heparan sulfate. Virology (1993) 3.42
CD4-deficient mice have reduced levels of memory cytotoxic T lymphocytes after immunization and show diminished resistance to subsequent virus challenge. J Virol (1996) 3.39
Immune adherence by the fourth component of complement. Science (1969) 3.34
Monoclonal antibodies to lymphocytic choriomeningitis and pichinde viruses: generation, characterization, and cross-reactivity with other arenaviruses. Virology (1981) 3.26
Virus-lymphocyte interactions. IV. Molecular characterization of LCMV Armstrong (CTL+) small genomic segment and that of its variant, Clone 13 (CTL-). Virology (1988) 3.22
Pathogenesis of of cytomegalovirus infection. I. Activation of virus from bone marrow-derived lymphocytes by in vitro allogenic reaction. J Exp Med (1975) 3.13
Fine mapping of an immunodominant domain in the transmembrane glycoprotein of human immunodeficiency virus. J Virol (1987) 2.97
The reaction of monomeric and aggregated immunoglobulins with C1. Immunochemistry (1971) 2.96
Complement activation by beta-amyloid in Alzheimer disease. Proc Natl Acad Sci U S A (1992) 2.84
Molecular definition of a major cytotoxic T-lymphocyte epitope in the glycoprotein of lymphocytic choriomeningitis virus. J Virol (1988) 2.82
Molecular analyses of a five-amino-acid cytotoxic T-lymphocyte (CTL) epitope: an immunodominant region which induces nonreciprocal CTL cross-reactivity. J Virol (1989) 2.79
Neurologic disease induced in transgenic mice by cerebral overexpression of interleukin 6. Proc Natl Acad Sci U S A (1993) 2.79
Analyses of the cytotoxic T lymphocyte responses to glycoprotein and nucleoprotein components of lymphocytic choriomeningitis virus. Virology (1988) 2.76
Purification and radiolabeling of human C1q. J Immunol (1981) 2.75
NP and L proteins of lymphocytic choriomeningitis virus (LCMV) are sufficient for efficient transcription and replication of LCMV genomic RNA analogs. J Virol (2000) 2.74
Organ-specific selection of viral variants during chronic infection. J Exp Med (1988) 2.71
Viral cross talk: intracellular inactivation of the hepatitis B virus during an unrelated viral infection of the liver. Proc Natl Acad Sci U S A (1996) 2.68
An essential role for type 1 interferon-gamma in terminating persistent viral infection. Virology (1995) 2.60
How virus induces a rapid or slow onset insulin-dependent diabetes mellitus in a transgenic model. Immunity (1994) 2.56
The antibody response of mice to murine leukemia virus in spontaneous infection: absence of classical immunologic tolerance (AKR mice-complement-fixing antibodies-lymphocytic choriomeningitis virus-immunofluorescence-glomerular deposits of antigen-antibody complexes). Proc Natl Acad Sci U S A (1972) 2.54
Molecular characterization of the genomic S RNA segment from lymphocytic choriomeningitis virus. Virology (1987) 2.53
Viral persistence in neurons explained by lack of major histocompatibility class I expression. Science (1991) 2.51
A comparison of methods for the molecular quantitation of the fourth component of human complement. Immunochemistry (1968) 2.44
Histocompatibility-linked genetic control of disease susceptibility. Murine lymphocytic choriomeningitis virus infection. J Exp Med (1973) 2.39
The classical complement pathway: activation and regulation of the first complement component. Adv Immunol (1985) 2.38
Lysis of RNA tumor viruses by human serum: direct antibody-independent triggering of the classical complement pathway. J Exp Med (1976) 2.34
Replication and persistence of measles virus in defined subpopulations of human leukocytes. J Virol (1975) 2.30
The primary structure of the lymphocytic choriomeningitis virus L gene encodes a putative RNA polymerase. Virology (1989) 2.25
Virus neutralization and virus-induced immune complex disease. Virus-antibody union resulting in immunoprotection or immunologic injury--two sides of the same coin. Prog Med Virol (1975) 2.23
The free-fillet flap for reconstruction of the upper extremity. Plast Reconstr Surg (1994) 2.23
CD40L-deficient mice show deficits in antiviral immunity and have an impaired memory CD8+ CTL response. J Exp Med (1996) 2.21
The second component of human complement (C2): quantitative molecular analysis of its reactions in immune hemolysis. Immunochemistry (1970) 2.18
Surface markers on human B and T lymphocytes. VIII. Association between complement and Epstein-Barr virus receptors on human lymphoid cells. Scand J Immunol (1976) 2.18
The effect of induced chronic viral infections on the immunologic diseases of New Zealand mice. J Exp Med (1970) 2.16
Vaccination and protection from a lethal viral infection: identification, incorporation, and use of a cytotoxic T lymphocyte glycoprotein epitope. Virology (1990) 2.12
Molecular mimicry in virus infection: crossreaction of measles virus phosphoprotein or of herpes simplex virus protein with human intermediate filaments. Proc Natl Acad Sci U S A (1983) 2.12
Early events in the infection of human B lymphocytes by Epstein-Barr virus: the internalization process. Virology (1984) 2.11
Immunohistochemical study of allergic encephalomyelitis. Am J Pathol (1968) 2.10
Immunologic injury in measles virus infection. II. Suppression of immune injury through antigenic modulation. J Exp Med (1975) 2.09
Multiple isoforms of CD46 (membrane cofactor protein) serve as receptors for measles virus. Proc Natl Acad Sci U S A (1994) 2.08
Pathogenesis of the slow disease of the central nervous system associated with WM 1504 E virus. I. Relationship of strain susceptibility and replication to disease. Am J Pathol (1977) 2.08
Studies on human plasma C1 inactivator-enzyme interactions. I. Mechanisms of interaction with C1s, plasmin, and trypsin. J Clin Invest (1975) 2.07
Immunologic injury of cultured cells infected with measles virus. I. role of IfG antibody and the alternative complement pathway. J Exp Med (1975) 2.06
Molecularly engineered vaccine which expresses an immunodominant T-cell epitope induces cytotoxic T lymphocytes that confer protection from lethal virus infection. J Virol (1989) 2.05
Molecular analysis of the interaction of LCMV with its cellular receptor [alpha]-dystroglycan. J Cell Biol (2001) 2.03
Pathogenesis of murine cytomegalovirus infection: the macrophage as a permissive cell for cytomegalovirus infection, replication and latency. J Gen Virol (1979) 2.01
Techniques for decreasing scar formation and contractures in the burned patient. J Trauma (1971) 2.01
Tissue injury in lymphocytic choriomeningitis viral infection: virus-induced immunologically specific release of a cytotoxic factor from immune lymphoid cells. Virology (1970) 2.00
Protein structure of lymphocytic choriomeningitis virus: evidence for a cell-associated precursor of the virion glycopeptides. Virology (1979) 2.00
Virus-lymphocyte interaction: T cells of the helper subset are infected with lymphocytic choriomeningitis virus during persistent infection in vivo. J Virol (1987) 1.99
Complement associated peptidase activity of guinea pig serum. I. Role of complement components. J Immunol (1967) 1.97
Interactions between viruses and lymphocytes. I. In vivo replication of lymphocytic choriomeningitis virus in mononuclear cells during both chronic and acute viral infections. J Immunol (1978) 1.95
Molecular mimicry: frequency of reactivity of monoclonal antiviral antibodies with normal tissues. J Virol (1986) 1.95
Localization of cytomegalovirus proteins and genome during fulminant central nervous system infection in an AIDS patient. J Neuropathol Exp Neurol (1986) 1.94
Identification of an epitope in the major envelope protein of Epstein-Barr virus that mediates viral binding to the B lymphocyte EBV receptor (CR2). Cell (1989) 1.93
Mechanism of lymphocytic choriomeningitis virus entry into cells. Virology (1994) 1.93
Viruses disrupt functions of human lymphocytes. Effects of measles virus and influenza virus on lymphocyte-mediated killing and antibody production. J Exp Med (1984) 1.92
Human serum lyses RNA tumour viruses. Nature (1975) 1.92
Diagnosis of AIDS by using a 12-amino acid peptide representing an immunodominant epitope of the human immunodeficiency virus. J Infect Dis (1987) 1.91
Optimal lymphocytic choriomeningitis virus sequences restricted by H-2Db major histocompatibility complex class I molecules and presented to cytotoxic T lymphocytes. J Virol (1995) 1.90
Antibody-induced redistribution of measles virus antigens on the cell surface. J Immunol (1974) 1.89
Virus-induced alterations in homeostasis: alteration in differentiated functions of infected cells in vivo. Science (1982) 1.88
Site-specific antibodies define a cleavage site conserved among arenavirus GP-C glycoproteins. J Virol (1987) 1.87
Isolation and analysis of the mechanism of action of an inactivator of C4b in normal human serum. J Exp Med (1975) 1.86
A "string-of-beads" vaccine, comprising linked minigenes, confers protection from lethal-dose virus challenge. J Virol (1993) 1.86
Consumption of human complement components by complexes of IgG with protein A of Staphylococcus aureus. Immunochemistry (1973) 1.86
Differences in affinity of binding of lymphocytic choriomeningitis virus strains to the cellular receptor alpha-dystroglycan correlate with viral tropism and disease kinetics. J Virol (2001) 1.85
Characterization of lymphocytic choriomeningitis virus-binding protein(s): a candidate cellular receptor for the virus. J Virol (1992) 1.84
Complement-dependent proinflammatory properties of the Alzheimer's disease beta-peptide. J Exp Med (1998) 1.84
A novel opioid receptor site directed alkylating agent with irreversible narcotic antagonistic and reversible agonistic activities. J Med Chem (1980) 1.80
Active thymus derived suppressor lymphocytes in human cord blood. Nature (1977) 1.80